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Macropinocytosis has long been known as a primary method for cellular intake of
fluid-phase and membrane-bound bulk cargo. This review seeks to re-examine the
latest studies to emphasize how cancers exploit macropinocytosis to further their
tumorigenesis, including details in how macropinocytosis can be adapted to serve
diverse functions. Furthermore, this reviewwill also cover the latest endeavors in targeting
macropinocytosis as an avenue for novel therapeutics.
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INTRODUCTION
Macropinocytosis is an endocytic pathway that leads to internalization of large patches
of plasma membrane along with extracellular fluid through irregularly formed vesicles
called macropinosomes. When compared to endosomes originating from coated vesicles,
macropinosomes are significantly larger by a factor of up to a thousand-fold (Hansen and Nichols,
2009). Despite observations from as early as the 1930s that cancer cells exhibit hallmarks of
macropinocytosis (Lewis, 1937), macropinocytosis was largely viewed as a canonical pathway
for bulk-phase endocytosis. However, recent advances in research lead to surprising, direct
roles for macropinocytosis within tumorigenesis. Furthermore, increasing numbers of studies
demonstrated that macropinocytosis might play broader roles ranging from neurodegenerative
disease to pathogen infiltration into host cells. This review aims to shed light on how the various
aspects of macropinocytosis may be exploited by both cancers and anti-cancer therapeutics.
The Biomechanics of Membrane Ruffling and Macropinocytosis
One of the hallmarks of macropinocytosis is its reliance on the formation of expansive membrane
ruﬄes within the plasma membrane, which contrasts the canonical, endocytic pathways that
depend on coat proteins such as clathrin and caveolin (Doherty and McMahon, 2009). The
membrane ruﬄes facilitate formation of randomly sized vacuoles ranging from 0.2 to 5µm in
size, which are up to 50-fold larger than the average 0.1µm size exhibited in protein-coated
vesicles (Hewlett et al., 1994). Comprehensive reviews are available that cover the biomechanical
underpinnings of macropinocytosis in detail (Kerr and Teasdale, 2009; Lim and Gleeson, 2011).
Membrane ruﬄing is initiated by rapid polymerization of branching of actin filaments (Mullins
et al., 1998) and direct or indirect disruption of actin dynamics impacts macropinocytosis
(Seastone et al., 2001; Innocenti et al., 2004). Spatial regulation of macropinocytosis can be
aided by actin motor proteins, possibly by delivering vesicles and proteins to requisite sites of
membrane ruﬄing (Brzeska et al., 2016). Other spatial and temporal regulators include the Rho
superfamily of GTPases, such as Rac and Cdc42, along with lipid rafts and lipid components such
as phosphoinositides and cholesterol, phosphatidylinositol phosphates (PIPs), their accompanying
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kinases (PIKs) and phosphatases (Grimmer et al., 2002; Mañes
et al., 2003; Innocenti et al., 2004; Redelman-Sidi et al.,
2013; Levin et al., 2015; Viaud et al., 2016). The roles
of both phospholipids and phosphoinositides in not only
macropinocytosis but within general endocytosis have long been
investigated, with numerous, comprehensive reviews available
(Simonsen et al., 2001; Bohdanowicz and Grinstein, 2013). Lastly,
distinct forms of membrane ruﬄing may occur. In addition
to traditional membrane ruﬄing, another type, circular dorsal
ruﬄes, exhibits a single, transient wave of membrane ruﬄes
from the edges of the dorsal membrane that then constricts
into an annulus within a short time scale, is capable of
internalizing >50% of ligand-bound growth receptors within
minutes (Orth et al., 2006). It remains unclear exactly why
different forms of membrane ruﬄing occur and whether their
ensuing macropinosomes obey similar biomechanics compared
to macropinosomes originating from traditional forms of
membrane ruﬄing.
Despite uncovering multiple proteins that partake in the
signal transduction behind membrane ruﬄing, it remains
unclear how membrane ruﬄing is regulated. Questions
remain regarding how macropinocytosis can be specifically
activated in response to certain stimuli within distinct
cell populations. For example, macropinocytosis can have
dramatically different effects on distinct cell types such as
glioblastoma multiforme (GBM) and pancreatic cancer cells.
When macropinocytosis is upregulated in GBM cells by a
quinine-derivative chemical, Vacquinol-1, massive membrane
ruﬄing and macropinocytosis lead to cell death through
excessive vacuolization and deformations in the plasma
membrane (Kitambi et al., 2014). On the other hand, pancreatic
cancer cells develop increased macropinocytosis to enhance
cancer progression (Commisso et al., 2013). Interestingly,
Vacquinol-1 only induces massive macropinocytosis in GBM
cells and not fibroblasts or neurons, implicating the need
for specific protein players in macropinocytosis (Kitambi
et al., 2014). These studies largely implicate an involvement
of cell- and tissue-specific signal transduction pathways that
may differentially regulate macropinocytosis to suit their
differentiated functions. As discussed later in this review, tissue-
specific effects onmacropinocytosis can also be observed through
modulation of various proteins. Current understanding of the
biomechanics behind tissue-specific forms of macropinocytosis
remains murky at best.
After the commencement of membrane ruﬄing, folds
and buds of the plasma membrane can undergo fission to
yield macropinosomes. This fission can be accommodated
by the actin-associated protein, coronin, which helps form
macropinocytic vesicles and dissociates shortly after vesicle
fission from the plasma membrane (Hacker et al., 1997;
BoseDasgupta et al., 2015). Depending on their origin and cell
type, macropinosomes can either recycle back to the plasma
membrane to recycle cell surface receptors or merge with the
endosomal/lysosomal network (Schnatwinkel et al., 2004). The
intracellular itineraries of macropinosomes may significantly
overlap with clathrin-dependent, endocytic pathways, including
mergers with early endosomes and the endosomal recycling
complex (Donaldson et al., 2009). Multitudes of protein
regulators define each step of intracellular vesicle trafficking
and as a result, cell types with varying proteomic profiles
exhibit diverse, intracellular trafficking functions. Nevertheless,
it remains unclear how different cell types manage to achieve
different, regulated forms of macropinocytosis and how they can
specify the itineraries of macropinosomes.
Confirming the Involvement of
Macropinocytosis
As with other forms of endocytosis, macropinocytosis can
be microscopically observed with fluorescent molecules. This
method typically has allowed full observation of the entire
macropinocytosis pathway, beginning with the formation of
large endocytic vesicles at the cell surface and until endosomal
maturation, where intracellular vesicles coalesce with the
lysosomal network. Fluid-phase, soluble proteins and sugars
such as albumin and dextran, respectively, have served as
useful, fluorescent markers specific for macropinocytosis
(Racoosin and Swanson, 1992; Li et al., 2013). These molecules
can help implicate an involvement of macropinocytosis
by specifically colocalizing with novel, endocytosed cargo.
Endocytosed cargo that largely colocalize with either albumin
or dextran, instead of coated-vesicle cargo such as transferrin
or transferrin receptors, typically suggest macropinocytosis
involvement. Furthermore, solutes and receptors that have been
associated with macropinocytosis can potentially be used as
macropinocytic markers themselves. Examples of this include
immunofluorescence against macropinocytosis-dependent
cell-surface receptors, such as EGFR or EphA2, which have both
been used to induce or observe macropinocytosis (Berger et al.,
2012; Ha et al., 2014). Not only can fluorescent microscopy
decipher macropinocytosis in vitro, but it can be additionally
employed for in vivo observation of macropinocytosis, including
within xenograft tumors in mice (Commisso et al., 2014).
Colocalization with macropinocytosis markers alone is
usually not enough to support macropinocytosis involvement.
In addition to colocalization, studies typically utilize
pharmacological reagents that have specific impacts on
macropinocytosis but not canonical, protein-coated endocytosis.
In this fashion, macropinocytosis-specific markers continue
to be internalized into cells while markers for canonical
protein-coated endocytosis, such as transferrin, suffer from
disrupted internalization. Cargos of interest that continue to
internalize into cells and colocalize with macropinocytosis-
specific markers despite pharmacological inhibition of canonical
forms of endocytosis strongly implicate an involvement
for macropinocytosis. Amilorides, for example, have been
shown to inhibit macropinocytosis while leaving other coat-
dependent, endocytic pathways intact (West et al., 1989; Dowrick
et al., 1993). Amiloride-based chemicals can inhibit Na+/H+
exchangers and consequently induce acidification at the plasma
membrane, which interferes with the activation of Rac and Cdc42
GTPases and subsequent actin remodeling (Koivusalo et al.,
2010). Chemicals that inhibit actin filament polymerization,
such as cytochalasin D, also inhibit macropinocytosis (Schliwa,
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1982; Heuser, 1989). Inhibitors that disrupt signal transduction
pathways that regulate membrane ruﬄing, such as inhibitors
against PI3K or PIP5K, also disrupt macropinocytosis (Araki
et al., 1996; Brown et al., 2001). Other chemicals can activate
macropinocytosis, such as aluminum fluoride, which activates
ADP ribosylation factor 6 (ARF6)-dependent macropinocytosis
(Radhakrishna et al., 1996). Other comprehensive reviews are
available that dissect the broad arsenal of pharmacological
reagents available to interrogate the numerous forms of
endocytic pathways (Ivanov, 2008). Primary disadvantages are
commonly associated with pharmacological reagents, however.
These typically include unknown, cellular side effects that often
reduce selectivity against specific forms of endocytosis.
In many cases, selective disruption of specific proteins
may lead to fewer side effects in dissecting the multiple
endocytic routes. Another review covers many protein and lipid
regulators that can be overexpressed, ablated, or mutated to
yield distinct effects on specific forms of endocytosis, including
macropinocytosis (Amyere et al., 2002). Depending on the both
the protein target and the severity of disruption, non-specific side
effects can be somewhat controlled.
In summary, fluorescent microscopy, pharmacological
disruption, and altered protein expression can all be employed to
confirm specific involvement of macropinocytosis vs. canonical,
endocytic pathways. The studies referenced throughout this
review largely utilize combinations of these methods to suggest
macropinocytosis involvement.
Activation of Macropinocytosis through
Receptors and Ligands
Depending on the cell type, macropinocytosis can be primarily
constitutive or induced. However, cells can commonly possess
both forms of macropinocytosis. Furthermore, varying cell
types can display wide ranges in macropinocytic activity. For
example, macrophages and dendritic cells often utilize high
levels of constitutive macropinocytosis to screen the extracellular
environment for pathogenic materials (Kerr and Teasdale, 2009).
On the other hand, neutrophils exhibit increased levels of
macropinocytosis when sensing foreign pathogens, which might
also aid in their ability to ingest pathogens (Lim and Gleeson,
2011).
Macropinocytosis is often mediated through stimulation of
cell surface receptors. These include receptor tyrosine kinase
(RTK) family receptors, where exosomes shed by cancer cells
can internalize into distant cancer cells in a paracrine fashion
through binding with RTKs (Li et al., 2010; Koumakpayi et al.,
2011; Nakase et al., 2015), cell-surface proteoglycans which
macropinocytose ligands containing closely spaced, basic amino
acids such as lysine, arginine, and histidine (Magzoub et al.,
2006), and G-protein coupled receptors (GPCRs). Podocytes and
colorectal cancer cells both activate macropinocytosis through
interactions between albumin-associated free fatty acids (FFAs)
and GPCRs (Wu et al., 2013; Chung et al., 2015). Dendritic cells
activatemacropinocytosis through another GPCR, S1P receptors,
to detect S1P and activate macropinocytosis (Ocaña-Morgner
et al., 2011). Certain cell types, including murine bone marrow
macrophages, do not require macropinocytosis stimulation and
instead have constitutive macropinocytosis (Norbury et al.,
1995).
Pathogens commonly display surface glycans to trigger
macropinocytosis through interactions with C-type lectin
receptors on antigen-presenting cells (Frenz et al., 2015). In
other instances, certain receptors bind to non-protein ligands
to activate macropinocytosis. For example, calcium is necessary
for inducing constitutive macropinocytosis in cells through G-
protein-coupled calcium-sensing receptors (Canton et al., 2016).
RTKs can also activate macropinocytosis through downstream
activation of a small GTPase, Rab5, to induce circular membrane
ruﬄes (Lanzetti et al., 2004).
Studies have demonstrated that proteins rich in arginine
amino acids may internalize into cells specifically via
macropinocytosis, possibly through basic interactions that
results in crosslinking (Nakase et al., 2004). Indeed, a 12-mer
arginine peptide, but not an 8-mer, induces macropinocytosis
by cross-linking CXCR4, the co-receptor for HIV-1 infection
into host cells (Tanaka et al., 2012). Additionally, cross-
linking the complement receptor, CD46, either via antibodies
or through pathogens such as the measles virus, induces
macropinocytosis (Crimeen-Irwin et al., 2003). Receptor cross-
linking and macropinocytosis activation may be more generic
than previously thought, as studies have shown that receptor
cross-linking enhances endocytosis (Moody et al., 2015).
Cancers Exploit Macropinocytosis to
Enhance Tumorigenesis
Numerous studies have firmly established concrete roles for Rac
in broad aspects of tumorigenesis, including cell survival and
growth, metastasis, and secondary tumor establishment (Mack
et al., 2011). Although Rac plays an important role as an upstream
activator of macropinocytosis, it is difficult to determine whether
macropinocytosis itself plays direct roles in the tumorigenic
functions of Rac. Rac can be activated by members of the
Ras (rat sarcoma) GTPase superfamily, which has long been
heralded as themost frequently mutated family of genes in cancer
(Stephen et al., 2014). Certain proteins, such as Abi1, can regulate
both macropinocytosis and protein coat-dependent endocytosis
and therefore it is likely that cancer cells can exploit multiple
endocytic pathways to establish and maintain their oncogenic
phenotypes (Innocenti et al., 2005).
Macropinocytosis serves as an efficient method to internalize
cell surface receptors, which cancer cells can exploit in their favor.
Cancers down-regulate cell-surface death receptors (DRs) via
macropinocytosis in an H-Ras dependent manner to evade TNF-
related apoptosis-inducing ligands (TRAILs) and subsequent
apoptosis (Chen et al., 2014). Interestingly, certain cancers with
either K- or H-Ras mutations can still be sensitive to TRAILs
as other receptors and downstream signaling components may
affect DR internalization via macropinocytosis (Drosopoulos
et al., 2005; Wang et al., 2015). Interestingly, cancers can
utilize macropinocytosis to internalize and activate receptors.
Prostate and breast cancer cells utilize macropinocytosis to
translocate a growth factor receptor, ErbB3, from the plasma
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membrane into the nucleus to further cellular proliferation
(Koumakpayi et al., 2011; Reif et al., 2016). It remains unclear
exactly how a membrane-bound receptor, possibly within a
vesicle, is imported into the nucleus. Additionally, H-Ras-
transformed fibroblasts internalize cell-surface platelet-derived
growth factor β-receptors (PDGFRβ) through macropinocytosis
to sensitize and enhance PDGFRβ activation, resulting in
increased anchorage-independent proliferation (Schmees et al.,
2012). In this case, PDFGFRβ phosphorylation is enhanced
only within macropinosomes, possibly due to macropinosomes-
specific PI3K activity (Schmees et al., 2012).
As macropinocytosis is an efficient and rapid form of
endocytosis, it is not surprising that cancers have exploited
it to replenish scarce nutrients for sustained propagation
within the tumor microenvironment. Ras-transformed
pancreatic cancer cells can upregulate macropinocytosis to
internalize and degrade albumin as a source of glutamine,
which is one of the most deprived metabolites within tumor
microenvironments (Commisso et al., 2013; Kamphorst et al.,
2015). Macropinocytosis appears to be the key player in
this phenomenon, as amiloride-based drugs that selectively
inhibit macropinocytosis while leaving other coat-dependent
endocytosis intact halted intake of albumin as a source of
glutamine for cancer cells (Commisso et al., 2013). In a similar
fashion to absorbing extracellular albumin, cancer cells have also
been shown to internalize extracellular ATP to aid in cancer
metabolism (Qian et al., 2014).
In addition to accumulating fluid-phase nutrients such as
proteins and ATP, cancer cells often internalize secreted vesicles,
called exosomes or microvesicles, through macropinocytosis
(Nakase et al., 2015). Exosomes can carry proteins, lipids, and
nucleic acids to serve as a form of extracellular communication
or metabolic replenishment (Tkach and Thery, 2016).
Many cancer types commonly exploit exosomes to enhance
cancer progression, typically by secreting exosomes that
internalize into other cancer cells and lead to favorable
environments that promote angiogenesis, metastasis, and
immunosuppression (Whiteside, 2016). For pancreatic cancer
cells, internalizing exosomes requires K-Ras and EGFR-
dependent macropinocytosis (Nakase et al., 2015). Alternatively,
exosomes originating from cancer cells can cause dysfunction in
normal cells. For example, pancreatic cancer cells shed exosomes
that can be internalized by β-cells to negatively impact insulin
secretion and further pancreatic cancers (Javeed et al., 2015).
Other cell types, such as cancer-associated fibroblasts, do not
require oncogenic K-Ras signaling to internalize exosomes (Zhao
et al., 2016).
Disrupting Macropinocytic Biochemistry
for Therapeutic Gains
Established links between macropinocytosis and cancers
have spurred the development of therapeutics targeting the
biochemical regulation behind macropinocytosis. This includes
therapeutics against the phosphoinositide biochemical pathways.
For example, RNA interference (RNAi) of one particular PIP5K,
Iγi2, leads to decreased oncogenic growth of breast cancer cells
(Thapa et al., 2013). In this case, Iγi2 coordinates with Src to
promote anchorage-independent growth. PIP5K may serve
divergent functions across multiple tissue types. For example,
disruption of PIP5Kα stunted membrane and protein recycling
from macropinosomes to the plasma membrane (Brown et al.,
2001). It remains unclear whether membrane and protein
recycling from macropinosomes contributes to anchorage-
independent growth in breast cancer cells. In another example,
the fungal metabolite wortmannin can block phosphoinositide-
3-kinase (PI3K) to inhibit scission of macropinosomes from
the cell surface, thus negatively effecting pancreatic cancer
motility, invasion, and metastasis (Araki et al., 1996; Teranishi
et al., 2009). Future studies investigating overlapping functions
across various phosphoinositide pathways within the context
of macropinocytosis across multiple cancer cell types can
potentially uncover additional therapeutic opportunities.
Another therapeutic venture includes disrupting cancer
cell metabolic activity through inhibition of macropinocytosis
(Zeitouni et al., 2016). However, cancer cells may additionally
employ other compensatory methods such as membrane
transporters and coat-dependent endocytosis to import
extracellular nutrients and proteins (Selwan et al., 2016).
Indeed, macropinocytosis can activate mTORC1 through
nutrient-intake in cancer cells that rely on metabolizing
endocytosed proteins in scarce amino-acid conditions (Palm
et al., 2015; Yoshida et al., 2015). Macropinosomes eventually
mature into increasingly acidic vacuoles, or lysosomes, for
subsequent degradation of consumed proteins (Racoosin and
Swanson, 1993). Hydroxychloroquine (HCQ), which inhibits
lysosomal acidification, negatively impacts both autophagy and
macropinocytosis-dependent scavenging and is currently under
investigation for its cancer therapeutic potential (Wolpin et al.,
2014). In this context, HCQ can be used to prevent cancer cells
from breaking down extracellular proteins to generate metabolic
substrates, thereby placing limitations on cancer cell metabolism
and growth (Kimmelman, 2015).
Lastly, other therapeutic ventures have shown that hyper-
stimulating macropinocytosis in cancer cells can lead to non-
apoptotic cell death known as methuosis (Li et al., 2010; Maltese
andOvermeyer, 2015). Methuosis can be induced through hyper-
activated Ras in glioblastoma cells, contributing to excessively
large macropinosomes that ultimately result in cell rupture
(Overmeyer et al., 2008). As Ras is commonly upregulated in
numerous cancers, glioblastoma cells must lack certain signal
transduction pathways that regulate macropinocytosis levels.
Uncovering these pathways, if they exist, should help expand the
arsenal of available targets in disrupting macropinocytosis.
Exploiting Macropinocytosis for Targeted
Delivery of Anti-Cancer Therapeutics
As cancer cells frequently employ macropinocytosis
to aid in receptor regulation and internalize essential
metabolites, extensive efforts have been underway in utilizing
macropinocytosis to deliver cytotoxic therapeutics specifically
into cancer cells. Some anti-cancer agents innately undergo
macropinocytosis, such as AS1411, which internalizes into
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various cancer cells through cell-surface nucleolin-dependent
mechanisms that activate macropinocytosis only in malignant
cells (Reyes-Reyes et al., 2010). Other therapeutics specifically
target cell surface receptors that may trigger macropinocytosis.
For example, therapeutic drugs conjugated with peptides that
target a combination of proteoglycans and keratinocyte growth
factor receptors (KGFR) can selectively internalize into and
kill KGFR-expressing lung cancer cells via macropinocytosis
(Iglesias and Koria, 2015).
Potent cancer therapeutics that exhibit excessive, systemic
toxicities or unstable pharmacokinetics from hydrophobic
profiles are excellent candidates for conjugation to yield
chemical conjugates or nanoparticles. The resultant conjugates or
nanoparticles can be engineered to yield greater specificity and
enhanced pharmacokinetics. In many other examples, synthetic
conjugates comprising any combination of small chemicals,
lipids, proteins, genetic components, and chemical scaffolds
can be developed to form nanoparticles that can then be
internalized into target cells via macropinocytosis. Nanoparticles,
which vary widely in composition, size, chemical charge, and
shape, all contribute to distinct, cellular specificities and in
endocytic mechanisms (Kettler et al., 2014). Larger nanoparticles
rely on macropinocytosis for efficient internalization but
smaller nanoparticles can traffic into cells through protein-
coated endocytosis as well. For example, nanoparticles featuring
paclitaxel fused to a chimeric peptide comprising an elastin-
like peptide with a hydrophilic peptide (CP-PTX) serve double
purposes in reducing the hydrophobic profile of paclitaxel
and in enhancing tumorigenic internalization of paclitaxel via
macropinocytosis (Bhattacharyya et al., 2015; Iglesias and Koria,
2015). Nanoparticles can also deliver genetic materials. For
example, polyethylene glycol (PEG)-based nanoparticles were
successfully used to deliver genes into cancer cells through
macropinocytosis (Walsh et al., 2006). Nanoparticle shapes play
important roles as well, as rod-like nanoparticles internalize
into cells independently from macropinocytosis (Liu et al.,
2016). Nanoparticles can also be targeted against specific cell
types by incorporating aptamers into lipid nanoparticles (Liang
et al., 2015). Similarly, nanoparticles conjugated with antibodies
targeting the collagen receptor, α2β1 integrin, lead to efficient
internalization via macropinocytosis (Kankaanpää et al., 2015).
As α2β1 integrins have been previously implicated in both cancer
stem cells and tumor angiogenesis, α2β1 integrin-targeting
nanoparticles could yield specific utility in cancer therapeutics
(Naci et al., 2015).
Another intriguing therapeutic front includes conjugating
cytotoxic payloads onto albumin primarily for enhancing drug
pharmacokinetics and because albumin has long been observed
to accumulate within solid tumors through macropinocytosis
(Kratz, 2008). An example includes the FDA-approved,
nanoparticle albumin-bound form of paclitaxel (nab-paclitaxel
or Abraxane R©) for treating multiple cancers. However, cancers
are still able to overcome these drugs through acquired
resistance, likely in differentially expressed proteins that regulate
macropinocytosis, including cytoskeletal and lipid metabolism
proteins (Zhao et al., 2015b) or through increased drug exporters
such as P-glycoprotein (Zhao et al., 2015a). Other albumin-based
conjugates targeting folate receptors also demonstrated efficient
delivery of cytotoxic compounds specifically into cancer cells
(Shi et al., 2014). Conjugates with non-albumin carriers have
also been successful, including paclitaxel poliglumex (PPX or
formerly Xyotax), comprising paclitaxel and polyglutamic acid
polymers. PPX has been effective against metastatic breast
cancers when used in combination with capecitabine (Northfelt
et al., 2014).
Another component commonly used for conjugation is
the poly-arginine peptide. As poly-arginine peptides induce
macropinocytosis and cancer cells generally have increased
macropinocytosis, efforts have been underway in conjugating
poly-arginine peptides with cytotoxic compounds. These
conjugates can be employed to deliver a variety of materials into
cells, including cytotoxic reagents against cancer cells (Biswas
et al., 2013; Liu et al., 2014), genetic materials (Zhang et al.,
2006; Hayashi et al., 2012), insulin (Liu et al., 2012; Zhang
et al., 2015), and liposomes across the blood brain barrier (Qin
et al., 2012). Interestingly, at least in HeLa cancer cells, poly-
arginine peptide entry into the cell cytosol occurs independently
from macropinocytosis (Zaro et al., 2006). This suggests that
poly-arginine peptides endocytosis may not be exclusive to
macropinocytosis, depending on both the cargo and cell type.
As cancers routinely internalize exosomes, a logical maneuver
includes formulating therapeutics that mimic exosomes.
Exosomes can be derived from same-host cells to avoid inducing
immune responses (Hall et al., 2016). Alternatively, exosomes
originating from dendritic cells may help elicit immune
responses by T and NK cells to specifically target cancer cells
(Pitt et al., 2016). Exosomes can be prepared in vitro, with
therapeutic proteins either electroporated into exosomes or
intracellularly incorporated through targeted overexpression
of genes in the cell cultures (Munson and Shukla, 2015).
Furthermore, lipid-membrane coat-based delivery systems that
resemble exosomes can be engineered in ways that promote
endosomal escape after macropinocytic entry into cells to enable
gene delivery into cells while avoiding degradation through
the lysosomal pathway (Khalil et al., 2007). Exosomes are
extremely useful in delivering payloads into cancer cells without
requiring advanced chemical conjugation as often required
in nanoparticles. Additionally, exosomes also offer greater
flexibility in packaging diverse combinations of cargoes.
Macropinocytosis in Pathogen-Host
Interaction and Neurodegenerative
Diseases
If cancers commonly exploit macropinocytosis for efficient
endocytosis of scarce nutrients and proteins, it is not surprising
that various pathogens also infiltrate into host cells through
this pathway. Pathogens such as viruses and bacteria commonly
enter human cells by activating macropinocytosis through
receptor-dependent means. Several examples include human
cytolomegavirus (Hetzenecker et al., 2016), Mycobacterium
smegmatis (Baltierra-Uribe et al., 2014), influenza A virus
(de Vries et al., 2011), vaccinia virus (Mercer and Helenius,
2008), infectious bursal disease virus (Gimenez et al., 2015),
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Salmonella (Francis et al., 1993; Chen et al., 1996), Zaire
Ebola virus (Hunt et al., 2011), and Kaposi’s sarcoma-associated
herpesvirus (Chakraborty et al., 2012). However, pathogens may
enter cells through additional endocytic routes in addition to
macropinocytosis. For example, African swine fever virus can
internalize intomacrophages through either macropinocytosis or
clathrin-mediated endocytosis (Hernáez et al., 2016). Organisms
that are larger than bacteria and viruses, such as protozoa,
can also infiltrate into host cells through macropinocytosis (de
Carvalho et al., 2015). In addition, Plasmodium sporozoites,
or malaria, also infiltrate into host hepatocytes by inducing
macropinocytosis through the EphA2 receptor (Kaushansky
et al., 2015), possibly through receptor cross-linking (Ha et al.,
2014).
Macropinocytosis appears to play vital roles across a
variety of neurodegenerative diseases as well, and this has
been comprehensively reviewed (Zeineddine and Yerbury,
2015). These diseases include Parkinson’s disease, Huntington’s
disease, amyotrophic lateral sclerosis, and Alzheimer’s disease.
Macropinocytosis allows neuronal cells to internalize protein
aggregates, possibly through cross-linking receptors that
remain largely unknown. Cross-linking of amyloid precursor
protein (APP) at the cell surface by antibodies leads to APP
internalization via Arf6-depedent macropinocytosis, potentially
FIGURE 1 | Cancer cells exploit macropinocytosis to fulfill diverse functions. (1) Cancer cells can utilize membrane ruffles, a hallmark of macropinocytosis, to
establish mobility and facilitate both anchorage independence and metastasis. (2) Cancer cells internalize metabolic nutrients, surface receptors, and transcription
activators. (3) Receptors involved in activating macropinocytosis are recycled back to the plasma membrane. (4) Non-recycled protein cargo and receptors are
degraded through the lysosomal network or in some instances, (5) certain receptors such as ErbB3 can be targeted for nuclear import to activate transcription.
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contributing to Alzheimer’s disease (Tang et al., 2015). In some
of these cases, heparin sulfate proteoglycans may serve as
the receptors for internalizing tau and α-synuclein fibrils to
commence intracellular fibrillization (Holmes et al., 2013). As
neurodegenerative fibrils commonly utilize macropinocytosis
to infiltrate neuronal cells, therapeutics that specifically inhibit
macropinocytosis in neurons sound logically promising.
However, such therapeutics are currently not available due
to the lack of knowledge in the signal transduction pathways
that define both tissue-specific and universal aspects of
macropinocytosis regulation. For example, therapeutics that
exhibit strong, inhibitory effects against macropinocytosis
may yield unintended side effects in disrupting constitutive
macropinocytosis of both macrophages and dendritic cells.
CONCLUSIONS
Cancer cells, in addition to pathogens and neurodegenerative
diseases, all exploit macropinocytosis for its efficiency in
endocytosis. In particular, cancer cells seem to possess increased
macropinocytic activity to fulfill diverse functions that include
metastasis, metabolism, and signal transduction (Figure 1).
For this reason, there has been an increased interest in the
field of macropinocytosis-dependent therapeutics, expanding the
available arsenal in selectively combating cancers. Additional
studies in how different cancers utilize macropinocytosis to
further disease progression could allow development of novel
therapeutics against specific cancers. On this same note, it
will be interesting to determine how macropinocytosis is
differentially regulated across various tissues and cell types.
Understanding how specific cell types can uniquely regulate
macropinocytosis may pave way for novel therapeutics that can
specifically target those cell types. Lastly, further research in how
macropinocytosis is uniquely regulated from other endocytic
pathways should facilitate targeted therapeutics without lending
systemic toxicity stemming from broadly inhibiting all endocytic
pathways.
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